Securing economic benefits and promoting conservation through bioprospecting

BioScience

Volumn 56, Issue 12, 2006, Pages 1005-1012

  Kursar, Thomas A ^a,b   Caballero George, Catherina C ^a   Capson, Todd L ^a   Cubilla Rios, Luis ^d   Gerwick, William H ^a,c   Gupta, Mahabir P ^d   Ibañez, Alicia ^a   Linington, Roger G ^c,e   McPhail, Kerry L ^f   Ortega Barrĩa, Eduardo ^e   Romero, Luz I ^e   Solis, Pablo N ^d   Coley, Phyllis D ^a,b  

^a SMITHSONIAN TROPICAL RESEARCH INSTITUTE   (Panama)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSIDAD DE PANAMÁ   (Panama)

^e INSTITUTO DE INVESTIGACIONES CIENTÍFICAS Y SERVICIOS DE ALTA TECNOLOGÍA   (Panama)

^f OREGON STATE UNIVERSITY   (United States)

Author keywords

Benefit sharing; Biodiversity conservation; Convention on Biological Diversity; Ecological economics; Ecosystem services

Indexed keywords

EID: 33845523502     PISSN: 00063568     EISSN: None     Source Type: Journal    
DOI: 10.1641/0006-3568(2006)56[1005:SEBAPC]2.0.CO;2     Document Type: Article

References (64)

1. Agnew B. 2000. When pharma merges, R&D is the dowry. Science 287: 1952-1953.
2. Aide TM, Grau HR. 2004. Globalization, migration and Latin American ecosystems. Science 305: 1915-1916.
3. Alavanja MC, Hoppin JA, Kamel F. 2004. Health effects of chronic pesticide exposure: Cancer and neurotoxicity. Annual Review of Public Health 25: 155-197.
4. Aldhous P. 1991. 'Hunting licence' for drugs. Nature 353: 290.
5. Angell M. 2004. The truth about the drug companies. New York Review of Books 51 (15 July): 52-58. (1 November 2006; www.nybooks.com/articles/17244)
6. Annan K. 2003. A challenge to the world scientists. Science 299: 1485.
7. Bar-Cohen Y, ed. 2006. Biomimetics: Biologically Inspired Technologies. Boca Raton (FL): CRC Press/Taylor and Francis.
8. Beattie AJ, Ehrlich PR. 2001. Wild Solutions: How Biodiversity Is Money in the Bank. New Haven (CT): Yale University Press.
9. Blaustein R. 2006. Genetic resources and the Convention on Biological Diversity. BioScience 56: 560-563.
10. [CBD] Convention on Biological Diversity. 2006. Access to Genetic Resources and Benefit-sharing Case Studies. (26 September 2006; www.biodiv.org/programmes/socio-eco/benefit/case-studies.asp)
11. Cherigo L, Polanco V, Ortega-Barria E, Heller MV, Capson TL, Cubilla-Rios L. 2005. Antitrypanosomal activity of a novel norlignan purified from Nectandra lineata. Natural Product Research 19: 373-377.
12. Cohen J. 2006. The new world of global health. Science 311: 162-167.
13. Coley PD, et al. 2003. Use of ecological criteria in designing plant collection strategies for drug discovery. Frontiers in Ecology and the Environment 1: 421-428.
14. Corbett Y, Herrera L, Gonzalez J, Cubilla L, Capson TL, Coley PD, Kursar TA, Romero LI, Ortega-Barria E. 2004. A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. American Journal of Tropical Medicine and Hygiene 70: 119-124.
15. Correa JE, Ríos CH, Castillo AR, Romero LI, Ortega-Barría E, Coley PD, Kursar TA, Heller MV, Gerwick WH, Cubilla-Rios L. 2006. Minor alkaloids from Guatteria dumetorum with antileishmanial activity. Planta Medica 72: 270-272.
16. Dalton R. 2004. Bioprospects less than golden. Nature 429: 598-600.
17. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22: 151-185.
18. Dinham B, Malik S. 2003. Pesticides and human rights. International Journal of Occupational and Environmental Health 9: 40-52.
19. The Economist. 2005. The scum of the Earth. The Economist. 7 April, 68-69.
20. Eddleston M, et al. 2002. Pesticide poisoning in the developing world-a minimum pesticides list. The Lancet 360: 1163-1167.
21. Edwards JL. 2004. Research and societal benefits of the Global Biodiversity Information Facility. BioScience 54: 486-487.
22. Erickson J. 2006. Translation research and drug development. Science 312: 997.
23. Fogarty International Center. 2006. International Cooperative Biodiversity Groups (ICBG). (26 September 2006; www.fic.nih.gov/programs/ research_grants/icbg/index.htm)
24. Gelb MH, Hol WGJ. 2002. Drugs to combat tropical protozoan parasites. Science 297: 343-344.
25. Gollin MA. 1993. The convention on biological diversity and intellectual property rights. Pages 289-324 in Reid WV, Laird SA, Meyer CA, Gámez R, Sittenfeld A, Janzen DH, Gollin MA, Juma C, eds. Biodiversity Prospecting: Using Genetic Resources for Sustainable Development. Washington (DC): World Resources Institute.
26. -. 1999. New rules for natural products research. Nature Biotechnology 17: 921-923.
27. Gómez-Pompa A. 2004. The role of biodiversity scientists in a troubled world. BioScience 54: 217-225.
28. Grajal A. 1999. Biodiversity and the nation state: Regulating access to genetic resources limits biodiversity research in developing countries. Conservation Biology 13: 6-10.
29. Gutiérrez M, Capson TL, Guzmán HM, Quiñoá E, Riguera R. 2004. L-galactose as a natural product: Isolation from a marine octocoral of the first α-L-galactosyl saponin. Tetrahedron Letters 45: 7833-7836.
30. Gutiérrez M, Capson TL, Guzmán HM, González J, Ortega-Barría E, Quiñoá E, Riguera R. 2005a. Leptolide, a new furanocembranolide diterpene from Leptogorgia alba. Journal of Natural Products 68: 614-616.
31. -. 2005b. Antiprotozoal activity against Plasmodium falciparum and Trypanosoma cruzi of aeroplysinin-1 isolated from the new sponge Aplysina chiriquiensis. Pharmaceutical Biology 43: 762-765.
32. Holmgren M, Schnitzer SA. 2004. Science on the rise in developing countries. PLoS Biology 2: 10-13.
33. Hussein AA, Bozzi B, Correa M, Capson TL, Kursar TA, Coley PD, Solis PN, Gupta MP. 2003a. Bioactive constituents from three Vismia species. Journal of Natural Products 66: 858-860.
34. Hussein AA, Gomez B, Ramos M, Heller M, Coley PD, Solis PN, Gupta MP. 2003b. Constituents of Hirea reclinata and their anti-HIV activity. Revista Latinoamericana de Química 31: 5-8.
35. Hussein AA, Barberena I, Capson TL, Kursar TA, Coley PD, Solis PN, Gupta MP. 2004. New cytotoxic naphthopyrane derivatives from Adenaria floribunda. Journal of Natural Products 67: 451-453.
36. Hussein AA, Barberena I, Correa M, Coley PD, Solis PN, Gupta MP. 2005. Cytotoxic flavonol glycosides from Triplaris cumingiana. Journal of Natural Products 68: 231-233.
37. Ivinson AJ. 2005. University investment in drug discovery. Science 310: 777.
38. Jambou R, et al. 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. The Lancet 366: 1960-1963.
39. Jankowski JE. 2001. Measurement and growth of R&D within the service economy. Journal of Technology Transfer 26: 323-336.
40. Kettler HE, Modi R. 2001. Building local research and development capacity for the prevention and cure of neglected diseases: The case of India. Bulletin of the World Health Organization 79: 742-747.
41. Koehn FE, Carter GT. 2005. The evolving role of natural products in drug discovery. Nature Reviews, Drug Discovery 4: 206-220.
42. Kursar TA, Coley PD. 2003. Convergence in defense syndromes of young leaves in tropical rainforests. Biochemical Systematics and Ecology 21: 929-949.
43. Kursar TA, Capson TL, Coley PD, Corley DG, Gupta MB, Harrison LA, Ortega-Barría E, Windsor DM. 1999. Ecologically guided bioprospecting in Panama. Pharmaceutical Biology 37 (suppl.): 114-126.
44. Laird SA, ten Kate K. 2002. Linking biodiversity prospecting and forest conservation. Pages 151-172 in Pagiola S, Bishop J, Landell-Mills N, eds. Selling Forest Environmental Services: Market-based Mechanisms for Conservation and Development. London: Earthscan.
45. Lila MA, Raskin I. 2005. Health-related interactions of phytochemicals. Journal of Food Science 70: R20-R27.
46. Marsh K. 1998. Malaria disaster in Africa. The Lancet 352: 924.
47. McChesney JD. 1996. Biological diversity, chemical diversity, and the search for new pharmaceuticals. Pages 11-18 in Balick MJ, Elisabetsky E, Laird SA, eds. Medicinal Resources of the Tropical Forest: Biodiversity and Its Importance to Human Health. New York: Columbia University Press.
48. Montenegro H, Gutiérrez M, Romero LI, Ortega-Barría E, Capson TL, Cubilla-Rios L. 2003. Aporphine alkaloids from Guatteria spp. with leishmanicidal activity. Planta Medica 69: 677-679.
49. Morel CM et al. 2005. Health innovation networks to help developing countries address neglected diseases. Science 309: 401-404.
50. Newman DJ, Cragg GM, Snader KM. 2003. Natural products as sources of new drugs over the period 1981-2002. Journal of Natural Products 66: 1022-1037.
51. [PIIPA] Public Interest Intellectual Property Advisors. 2006. (13 March 2006; http://piipa.org)
52. Rosenthal JP, Katz FN. 2004. Natural products research partnerships with multiple objectives in global biodiversity hotspots: Nine years of the International Cooperative Biodiversity Groups Program. Pages 458-466 in Bull A,ed. Microbial Diversity and Bioprospecting. Washington (DC): ASM Press.
53. Rosenthal JP, et al. 1999. Combining high-risk science with ambitious social and economic goals. Pharmaceutical Biology 37 (suppl.): 6-21.
54. ten Kate K, Laird SA. 1999. The Commercial Use of Biodiversity: Access to Genetic Resources and Benefit-Sharing. London: Earthscan.
55. Torres-Mendoza D, Urena Gonzalez LD, Ortega-Barría E, Capson TL, Cubilla Rios L. 2003. Five new cassane diterpenes from Myrospermum frutescens with activity against Trypanosoma cruzi. Journal of Natural Products 66: 928-932.
56. Torres-Mendoza D, Ureña Gonzalez LD, Ortega-Barría E, Coley PD, Kursar TA, Capson TL, McPhail K, Cubilla-Rios L. 2004. Novel cassane and cleistanthane diterpenes from Myrospermum frutescens: Absolute stereochemistry of the cassane diterpene series. Journal of Natural Products 67: 1711-1715.
57. Towie N. 2006. Malaria breakthrough raises spectre of drug resistance. Nature 440: 852-853.
58. Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, Pécoul B. 2001. Drugs for neglected diseases: A failure of the market and a public policy health failure? Tropical Medicine and International Health 6: 945-951.
59. [UNCTAD] United Nations Conference on Trade and Development. 2005. World Investment Report 2005: Transnational Corporations and the Intel-nationalization of R&D. New York: UNCTAD.
60. United Nations. 2003. World Urbanization Prospects: The 2003 Revision Population Database. (26 September 2006; http://esa.un.org/unup/)
61. Viotti R, Vigliano C, Armenti H, Segura E. 1994. Treatment of chronic Chagas' heart disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. American Heart Journal 127: 151-162.
62. Wei X, Rodríguez A, Baran P, Raptis R, Sáchez J, Ortega-Barría E, González J. 2004. Antiplasmodial cembradiene diterpenoids from a Southwestern Caribbean gorgonian octocoral of the genus Eunicea. Tetrahedron 60: 11813-11819.
63. Weiss B, Amler S, Amler RW. 2004. Pesticides. Pediatrics 113: 1030-1036.
64. Williams C, Espinosa OA, Montenegro H, Cubilla Rios L, Capson TL, Ortega-Barría E, Romero LI. 2003. Hydrosoluble formazan XTT: Its application to natural products drug discovery for Leishmania. Journal of Microbiological Methods 55: 813-816.